Application Value Analysis of Seven-Autoantibody Panel in the Lung Cancer Screening in Yunnan

Overview

Journal Comput Intell Neurosci

Specialty Biology

Date 2022 Jul 14

PMID 35832243

Authors

Wenrun Li

Yi Sun

Ning Xu

Affiliations

Soon will be listed here.

Abstract

Objective: To study the application value of seven-autoantibody (anti-CAGE, anti-GAGE7, anti-GBU4-5, anti-MAGE A1, anti-P53, and anti-PGP9.5, anti-SOX2) in lung cancer (LC) screening in Yunnan.

Methods: The clinical data of 329 lung cancer patients and 202 nonlung cancer controls in the First People's Hospital of Yunnan Province from November 2018 to April 2022 were retrospectively analyzed. The detection results of anti-CAGE, anti-GAGE7, anti-GBU4-5, anti-MAGE A1, anti-P53, anti-PGP9.5, and anti-SOX2 were collected. The receiver operating curve (ROC) was used to analyze the value of these seven-autoantibody in the detection of LC alone and in combination, and the area under the curve (AUC), sensitivity, specificity, and cut-off values were calculated.

Results: The levels of anti-CAGE, anti-GAGE7, anti-GBU4-5, anti-MAGE A1, anti-P53, anti-PGP9.5 and anti-SOX2 in LC patients were significantly higher than those in the controls, and the differences were statistically significant ( < 0.001). The AUC of anti-CAGE, anti-GAGE7, anti-GBU4-5, anti-MAGE A1, anti-P53, anti-PGP9.5, and anti-SOX2 for the diagnosis of LC were 0.586 (95% CI: 0.537-0.634, < 0.001), 0.620 (95% CI: 0.572-0.667, < 0.001), 0.570 (95% CI: 0.521-0.619, =0.007), 0.612 (95% CI: 0.563-0.660, < 0.007) 0.001), 0.561 (95% CI: 0.510-0.611, =0.019), 0.667 (95% CI: 0.619-0.715, < 0.001), 0.587 (95% CI: 0.538-0.636, < 0.001), respectively. The AUC of combined detection of LC was 0.719 (95% CI: 0.676-0.761, < 0.001). The positive rate of the combined detection of seven-autoantibody in the LC group was 48.02% (158/329), which was significantly higher than that of the control group (13.86% (28/202)), the difference was statistically significant ( = 64.183, < 0.001).

Conclusion: The individual detection and combined detection of the seven-autoantibody have a certain value in the diagnosis of LC in Yunnan, and it can provide a certain reference for clinical LC screening.

Citing Articles

Clinical application of serum seven tumour-associated autoantibodies in patients with pulmonary nodules.

Hu K, Gao L, Zhang R, Lu M, Zhou D, Xie S Heliyon. 2024; 10(9):e30576.

PMID: 38765082 PMC: 11098830. DOI: 10.1016/j.heliyon.2024.e30576.

Retracted: Application Value Analysis of Seven-Autoantibody Panel in the Lung Cancer Screening in Yunnan.

Intelligence And Neuroscience C Comput Intell Neurosci. 2023; 2023:9849272.

PMID: 38074380 PMC: 10700724. DOI: 10.1155/2023/9849272.

References

Tang Z, Ling Z, Wang C, Wu Y, Kong J . Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis. PLoS One. 2017; 12(7):e0182117. PMC: 5547718. DOI: 10.1371/journal.pone.0182117. View

Yang D, Zhang Y, Hong Q, Hu J, Li C, Pan B . Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients. Cancer. 2015; 121 Suppl 17:3113-21. DOI: 10.1002/cncr.29551. View

Chapman C, Healey G, Murray A, Boyle P, Robertson C, Peek L . EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012; 33(5):1319-26. PMC: 3460172. DOI: 10.1007/s13277-012-0379-2. View

Kao C, Badve S, Ulbright T . The utility of immunostaining for NUT, GAGE7 and NY-ESO-1 in the diagnosis of spermatocytic seminoma. Histopathology. 2014; 65(1):35-44. DOI: 10.1111/his.12365. View

Ren S, Zhang S, Jiang T, He Y, Ma Z, Cai H . Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncoimmunology. 2018; 7(2):e1384108. PMC: 5749655. DOI: 10.1080/2162402X.2017.1384108. View

Por E, Byun H, Lee E, Lim J, Jung S, Park I . The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by up-regulating cyclins D1 and E in an AP-1- and E2F-dependent manner. J Biol Chem. 2010; 285(19):14475-85. PMC: 2863237. DOI: 10.1074/jbc.M109.084400. View

Jahanban-Esfahlan R, Seidi K, Monfaredan A, Shafie-Irannejad V, Mesgari Abbasi M, Karimian A . The herbal medicine Melissa officinalis extract effects on gene expression of p53, Bcl-2, Her2, VEGF-A and hTERT in human lung, breast and prostate cancer cell lines. Gene. 2017; 613:14-19. DOI: 10.1016/j.gene.2017.02.034. View

Heo C, Bahk Y, Cho E . Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. BMB Rep. 2012; 45(12):677-85. PMC: 4133814. DOI: 10.5483/bmbrep.2012.45.12.236. View

Wu W, Yie S, Ye S, Xie K, Zhang J, Cao M . An Autoantibody Against Human DNA-Topoisomerase I Is a Novel Biomarker for Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018; 105(6):1664-1670. DOI: 10.1016/j.athoracsur.2018.01.036. View

10.

Wang H, Yang X, Sun G, Yang Q, Cui C, Wang X . Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma. Front Oncol. 2021; 11:661043. PMC: 8462091. DOI: 10.3389/fonc.2021.661043. View

11.

Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y . PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res. 2002; 8(1):192-5. View

12.

. [Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (Edition 2018)]. Zhonghua Zhong Liu Za Zhi. 2019; 40(12):935-964. DOI: 10.3760/cma.j.issn.0253-3766.2018.12.012. View

13.

Wen W, Liu G, Jin K, Hu X . TGF-β1 induces PGP9.5 expression in CAFs to promote the growth of colorectal cancer cells. Oncol Rep. 2016; 37(1):115-122. DOI: 10.3892/or.2016.5238. View

14.

Zhang X, Liu M, Zhang X, Wang Y, Dai L . Autoantibodies to tumor-associated antigens in lung cancer diagnosis. Adv Clin Chem. 2021; 103:1-45. DOI: 10.1016/bs.acc.2020.08.005. View

15.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

16.

Du Q, Yu R, Wang H, Yan D, Yuan Q, Ma Y . Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer. Clin Respir J. 2018; 12(6):2020-2028. DOI: 10.1111/crj.12769. View

17.

Mu Y, Xie F, Sun T . Clinical value of seven autoantibodies combined detection in the diagnosis of lung cancer. J Clin Lab Anal. 2020; 34(8):e23349. PMC: 7439340. DOI: 10.1002/jcla.23349. View

18.

Duffy M, Synnott N, Crown J . Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017; 83:258-265. DOI: 10.1016/j.ejca.2017.06.023. View

19.

Ning J, Ge T, Jiang M, Jia K, Wang L, Li W . Early diagnosis of lung cancer: which is the optimal choice?. Aging (Albany NY). 2021; 13(4):6214-6227. PMC: 7950268. DOI: 10.18632/aging.202504. View

20.

Ouyang R, Wu S, Zhang B, Wang T, Yin B, Huang J . Clinical value of tumor-associated antigens and autoantibody panel combination detection in the early diagnostic of lung cancer. Cancer Biomark. 2021; 32(3):401-409. DOI: 10.3233/CBM-210099. View